David Waxman

Publications

• Widespread Epigenetic Changes to the Enhancer Landscape of Mouse Liver Induced by a Specific Xenobiotic Agonist Ligand of the Nuclear Receptor CAR
• Insulation of gene expression by CTCF and cohesin-based subTAD (ubiquitous intra-TAD) loop structures in mouse liver
• Widespread dysregulation of long non-coding genes associated with fatty acid metabolism, cell division, and immune response gene networks in xenobiotic-exposed rat liver
• Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
• Genetic factors contributing to extensive variability of sex-specific hepatic gene expression in Diversity Outbred mice
• CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model
• Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting
• Sex-biased long non-coding RNAs negatively correlated with sex-opposite protein coding gene co-expression networks in Diversity Outbred mouse liver
• Impact of 3D genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver
• Computational prediction of CTCF/cohesin-based intra-TAD loops that insulate chromatin contacts and gene expression in mouse liver
• Impact of CAR Agonist Ligand TCPOBOP on Mouse Liver Chromatin Accessibility
• Genetic factors contributing to extensive variability of sex-specific hepatic gene expression in Diversity Outbred mice
• STAT5 regulation of sex-dependent hepatic CpG methylation at distal regulatory elements mapping to sex-biased genes
• Sex-Biased lncRNAs Inversely Correlate With Sex-Opposite Gene Coexpression Networks in Diversity Outbred Mouse Liver
• Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2
• Delicate balances in cancer chemotherapy: Modeling immune recruitment and emergence of systemic drug resistance
• Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
• Hepatic Long Intergenic Noncoding RNAs: High Promoter Conservation and Dynamic, Sex-Dependent Transcriptional Regulation by Growth Hormone.
• Cross Talk Between GH-Regulated Transcription Factors HNF6 and CUX2 in Adult Mouse Liver.
• Early programing of uterine tissue by bisphenol A: Critical evaluation of evidence from animal exposure studies.
• Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory.
• Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
• Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
• Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
• Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
• Adenoviral vectors for prodrug activation-based gene therapy for cancer.
• H460 non-small cell lung cancer stem-like holoclones yield tumors with increased vascularity.
• Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to metabolic stress
• STAT5 Regulation of Sex-Dependent Hepatic CpG Methylation at Distal Regulatory Elements Mapping to Sex-Biased Genes
• Feminization of Male Mouse Liver by Persistent Growth Hormone Stimulation: Activation of Sex-Biased Transcriptional Networks and Dynamic Changes in Chromatin States
• Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver
• Correction: Chemical and Hormonal Effects on STAT5b- Dependent Sexual Dimorphism of the Liver Transcriptome.
• Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event.
• Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome.
• Changes in mouse uterine transcriptome in estrus and proestrus.
• Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver.
• Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
• Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
• Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2
• Impact of 3-dimensional genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver
• Impact of 3D genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver
• Harnessing natural variation to identify cis regulators of sex-biased gene expression in a multi-strain mouse liver model
• Optical scattering as an early marker of apoptosis during chemotherapy and antiangiogenic therapy in murine models of prostate and breast cancer
• Global analysis of expression, maturation and subcellular localization of mouse liver transcriptome identifies novel sex-biased and TCPOBOP-responsive long non-coding RNAs
• MAnorm2 for quantitatively comparing groups of ChIP-seq samples
• Impact of 3D genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver
• Harnessing natural variation to identify cis regulators of sex-biased gene expression in a multi-strain mouse liver model
• Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancer
• Interplay between murine sex-biased gene expression and hepatic zonation revealed by single nucleus RNA sequencing
• Impact of neonatal activation of nuclear receptor CAR (Nr1i3) on Cyp2 gene expression in adult mouse liver
• Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
• Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
• Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
• Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
• Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice.
• The induction of atherogenic dyslipidaemia in poloxamer 407-treated mice is not mediated through PPARalpha.
• Sex-specific early growth hormone response genes in rat liver.
• Interactions of methoxyacetic acid with androgen receptor.
• Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver.
• Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
• Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression.
• Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
• Progress and prospects: gene therapy clinical trials (part 2).
• Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.
• Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis.
• Conditionally replicating adenoviruses for cancer treatment.
• Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver.
• Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus.
• A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
• Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
• Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes.
• Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood.
• Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
• DNase I digestion of isolated nulcei for genome-wide mapping of DNase hypersensitivity sites in chromatin.
• Isolation of nuclei for use in genome-wide DNase hypersensitivity assays to probe chromatin structure.
• Child health, developmental plasticity, and epigenetic programming.
• Cytochrome P450 2B1 mediates complement-dependent sublytic injury in a model of membranous nephropathy.
• Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.
• Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease.
• MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets.
• Unbiased, Genome-Wide In Vivo Mapping of Transcriptional Regulatory Elements Reveals Sex Differences in Chromatin Structure Associated with Sex-Specific Liver Gene Expression.
• VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
• Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver.
• Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 2: early spectral changes during apoptosis are linked to apoptotic volume decrease.
• Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 1: early and late spectral changes are indicative of the presence of apoptosis in cell cultures.
• Complex modulation of androgen responsive gene expression by methoxyacetic acid.
• Antiangiogenesis enhances intratumoral drug retention.
• PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis.
• Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression.
• Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
• Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
• Impact of methoxyacetic acid on mouse Leydig cell gene expression.
• Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells.
• Intrinsic sex differences in the early growth hormone responsiveness of sex-specific genes in mouse liver.
• Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone.
• The structural basis of pregnane X receptor binding promiscuity.
• Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5.
• Sex differences in the expression of hepatic drug metabolizing enzymes.
• Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites.
• Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.
• Catalytic assays for human cytochrome P450: an introduction.
• Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).
• Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
• Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene.
• Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha.
• Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization.
• Cancer chemotherapy and drug metabolism.
• Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.
• Computational screening of phthalate monoesters for binding to PPARgamma.
• Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450.
• Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.
• Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
• Growth hormone regulation of sex-dependent liver gene expression.
• Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
• Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis.
• Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families.
• An isocratic high-performance liquid chromatography assay for CYP7A1-catalyzed cholesterol 7alpha-hydroxylation.
• Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.
• Thin-layer chromatography analysis of human CYP3A-catalyzed testosterone 6beta-hydroxylation.
• Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation.
• CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection.
• CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
• Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography.
• Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation.
• High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.
• Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
• Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate.
• Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice.
• Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
• Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide.
• Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
• Pregnane X receptor-mediated transcription.
• Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2.
• Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
• Sexual dimorphism of rat liver nuclear proteins: regulatory role of growth hormone.
• Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
• Environmental phthalate monoesters activate pregnane X receptor-mediated transcription.
• Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin J2.
• Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450.
• trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals.
• Cytochrome p450-based gene therapies for cancer.
• Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice.
• Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
• Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes.
• Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy.
• Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis.
• Harnessing apoptosis for improved anticancer gene therapy.
• Sexual dimorphism of hepatic gene expression: novel biological role of KRAB zinc finger repressors revealed.
• Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.
• Activation of PPARalpha and PPARgamma by environmental phthalate monoesters.
• CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
• Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids.
• Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
• Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
• Evaluation of thyroid hormone effects on liver P450 reductase translation.
• Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
• Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid omega-hydroxylase in STAT5b(-/-) mice: cross-talk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways.
• Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity.
• Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3beta: impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression.
• Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
• Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
• Transcriptional induction of hepatic NADPH: cytochrome P450 oxidoreductase by thyroid hormone.
• An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.
• P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.
• Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
• Pulsatility of growth hormone (GH) signalling in liver cells: role of the JAK-STAT5b pathway in GH action.
• Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
• 8 tumor models for evaluation of p450 gene therapy in vivo.
• 7 in vitro methods for evaluation of p450-based anticancer gene therapy.
• Construction of p450-expressing tumor cell lines using retroviruses.
• Selection of cytochrome p450 genes for use in prodrug activation-based cancer gene therapy.
• Growth hormone pulse-activated STAT5 signalling: a unique regulatory mechanism governing sexual dimorphism of liver gene expression.
• SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms.
• trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals.
• Growth hormone, but not prolactin, maintains, low-level activation of STAT5a and STAT5b in female rat liver.
• Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
• STAT5 signaling in sexually dimorphic gene expression and growth patterns.
• High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations.
• Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
• STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain.
• Cytochrome P450-based cancer gene therapy: recent advances and future prospects.
• Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption.
• Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
• Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
• In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
• Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation.
• Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b.
• Termination of growth hormone pulse-induced STAT5b signaling.
• Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability.
• Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
• Long-term enhancement of cytochrome P450 2B1/2 expression in rat hepatocyte spheroids through adenovirus-mediated gene transfer.
• Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression.
• Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity.
• Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.
• P450 enzyme expression patterns in the NCI human tumor cell line panel.
• Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells.
• Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone.
• Synergistic action of hepatocyte nuclear factors 3 and 6 on CYP2C12 gene expression and suppression by growth hormone-activated STAT5b. Proposed model for female specific expression of CYP2C12 in adult rat liver.
• Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.
• An isocratic high-performance liquid chromatographic assay for CYP7A1-catalyzed cholesterol 7 alpha-hydroxylation.
• Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription.
• Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
• Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism.
• Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells.
• Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats.
• 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels.
• Changes in cytochromes P-450, 2E1, 2B1, and 4A, and phospholipases A and C in the intragastric feeding rat model for alcoholic liver disease: relationship to dietary fats and pathologic liver injury.
• Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene.
• Rat liver cytochrome P450 2B3: structure of the CYP2B3 gene and immunological identification of a constitutive P450 2B3-like protein in rat liver.
• Dehydroepiandrosterone 3 beta-sulphate is an endogenous activator of the peroxisome-proliferation pathway: induction of cytochrome P-450 4A and acyl-CoA oxidase mRNAs in primary rat hepatocyte culture and inhibitory effects of Ca(2+)-channel blockers.
• Growth hormone-dependent and -independent sexually dimorphic regulation of phenobarbital-induced hepatic cytochromes P450 2B1 and 2B2.
• Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.
• Use of reverse transcription-polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods.
• Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation.
• Interaction of a novel sex-dependent, growth hormone-regulated liver nuclear factor with CYP2C12 promoter.
• Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
• Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase.
• Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator.
• Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
• Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
• Sex-dependent expression and growth hormone regulation of class alpha and class mu glutathione S-transferase mRNAs in adult rat liver.
• Induction of microsomal and peroxisomal enzymes by dehydroepiandrosterone and its reduced metabolite in rats.
• Cimetidine prevents alcoholic hepatic injury in the intragastric feeding rat model.
• Multiple, functional DBP sites on the promoter of the cholesterol 7 alpha-hydroxylase P450 gene, CYP7. Proposed role in diurnal regulation of liver gene expression.
• Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
• Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases.
• CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reversed-phase ion-pair high-performance liquid chromatography with fluorescence detection.
• Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography.
• High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6 alpha-hydroxylation.
• Determination of the CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
• Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate.
• Catalytic assays for human cytochrome P450.
• Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
• Spectrofluorometric analysis of CYP2A6-catalyzed coumarin 7-hydroxylation.
• Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
• Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
• Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families.
• Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.
• Thin-layer chromatographic analysis of human CYP3A-catalyzed testosterone 6 beta-hydroxylation.
• Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation.
• Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5'-flank of the oxidoreductase gene.
• Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.
• Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression.
• Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
• Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
• Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.
• Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation.
• Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
• P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.
• Growth hormone regulation of male-specific rat liver P450s 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate.
• Mechanisms of cyclophosphamide action on hepatic P-450 expression.
• Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
• The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature.
• Regulation of liver-specific steroid metabolizing cytochromes P450: cholesterol 7α-hydroxylase, bile acid 6β-hydroxylase, and growth hormone-responsive steroid hormone hydroxylases.
• Gene-specific oligonucleotide probes for alpha, mu, pi, and microsomal rat glutathione S-transferases: analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs.
• Monoclonal antibodies to rat liver microsomal cytochrome b5.
• Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats.
• Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanisms?
• Hormonal perturbations in patients with testicular cancer treated with cisplatin.
• Phenobarbital induction of cytochrome P-450 gene expression.
• Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone.
• Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes.
• Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms.
• Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s.
• Sequence requirements for cytochrome P-450IIB1 catalytic activity. Alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine.
• Xenobiotic induction of P-450 PB-4 (IIB1) and P-450c (IA1) and associated monooxygenase activities in primary cultures of adult rat hepatocytes.
• Interpulse interval in circulating growth hormone patterns regulates sexually dimorphic expression of hepatic cytochrome P450.
• Differential effects of neonatally administered glutamate on the ultradian pattern of circulating growth hormone regulating expression of sex-dependent forms of cytochrome P450.
• N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.
• Phenobarbital induction of cytochromes P-450. High-level long-term responsiveness of primary rat hepatocyte cultures to drug induction, and glucocorticoid dependence of the phenobarbital response.
• Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review.
• Hepatic P-450 cholesterol 7 alpha-hydroxylase. Regulation in vivo at the protein and mRNA level in response to mevalonate, diurnal rhythm, and bile acid feedback.
• Influence of lipophilicity and carboxyl group content on the rate of hydroxylation of methotrexate derivatives by aldehyde oxidase.
• Depletion of serum growth hormone in adult female rats by neonatal monosodium glutamate treatment without loss of female-specific hepatic enzymes P450 2d (IIC12) and steroid 5 alpha-reductase.
• Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
• Biotransformation of N,N',N''-triethylenethiophosphoramide: oxidative desulfuration to yield N,N',N''-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase.
• Participation of two structurally related enzymes in rat hepatic microsomal androstenedione 7 alpha-hydroxylation.
• Signalling elements in the ultradian rhythm of circulating growth hormone regulating expression of sex-dependent forms of hepatic cytochrome P450.
• Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5 that regiospecifically inhibit steroid metabolism.
• Detoxification of lithocholic acid. Elucidation of the pathways of oxidative metabolism in rat liver microsomes.
• Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
• Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone.
• Female-predominant rat hepatic P-450 forms j (IIE1) and 3 (IIA1) are under hormonal regulatory controls distinct from those of the sex-specific P-450 forms.
• Androgen hydroxylation catalysed by a cell line (SD1) that stably expresses rat hepatic cytochrome P-450 PB-4 (IIB1).
• Changes in microsomal phospholipases and arachidonic acid in experimental alcoholic liver injury: relationship to cytochrome P-450 2E1 induction and conjugated diene formation.
• Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
• Irreversible suppression of growth hormone-dependent cytochrome P450 2C11 in adult rats neonatally treated with monosodium glutamate.
• Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes.
• The lithocholic acid 6 beta-hydroxylase cytochrome P-450, CYP 3A10, is an active catalyst of steroid-hormone 6 beta-hydroxylation.
• Distinct forms of cytochrome P-450 are responsible for 6 beta-hydroxylation of bile acids and of neutral steroids.
• Hepatic P450 expression in hypothyroid rats: differential responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid hormone.
• P450-catalyzed steroid hydroxylation: assay and product identification by thin-layer chromatography.
• P450 phosphorylation in isolated hepatocytes and in vivo.
• Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes.
• Pretranslational control by thyroid hormone of rat liver steroid 5 alpha-reductase and comparison to the thyroid dependence of two growth hormone-regulated CYP2C mRNAs.
• Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase.
• Cytochrome P-450-dependent oxidation of arachidonic acid to 16-, 17-, and 18-hydroxyeicosatetraenoic acids.
• Regulation and ligand-binding specificities of two sex-specific bile acid-binding proteins of rat liver cytosol.
• Pituitary regulation of the male-specific steroid 6 beta-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational leve;.
• Hormonal regulation of levels of the messenger RNA encoding hepatic P450 2c (IIC11), a constitutive male-specific form of cytochrome P450.
• Primary structure of the COOH-terminal membranous segment of a penicillin-sensitive enzyme purified from two Bacilli.
• Posttranslational modification of hepatic cytochrome P-450. Phosphorylation of phenobarbital-inducible P-450 forms PB-4 (IIB1) and PB-5 (IIB2) in isolated rat hepatocytes and in vivo.
• Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation.
• Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase.
• Antibodies targeted against hypervariable and constant regions of cytochromes P450IIB1 and P450IIB2.
• Interaction of anticancer drugs with hepatic monooxygenase enzymes.
• Phosphorylation of carcinogen metabolizing enzymes: regulation of the phosphorylation status of the major phenobarbital inducible cytochromes P-450 in hepatocytes.
• Gene conversion and differential regulation in the rat P-450 IIA gene subfamily. Purification, catalytic activity, cDNA and deduced amino acid sequence, and regulation of an adult male-specific hepatic testosterone 15 alpha-hydroxylase.
• Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics.
• Antibodies to liver/kidney microsome1 in chronic active hepatitis recognize specific forms of hepatic cytochrome P-450.
• Feminization of rat hepatic P-450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes.
• Adult male-specific and neonatally programmed rat hepatic P-450 forms RLM2 and 2a are not dependent on pulsatile plasma growth hormone for expression.
• Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.
• Induction of rat cytochrome P-450 3 and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl.
• Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression.
• Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations.
• Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms.
• Xenobiotic metabolizing enzymes are not restricted to parenchymal cells in rat liver.
• Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes.
• Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme.
• Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver.
• Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5.
• Chiral sulfoxidations catalyzed by rat liver cytochromes P-450.
• Penicillin is an active-site inhibitor for four genera of bacteria.
• High-molecular-weight penicillin-binding proteins from membranes of bacilli.
• Secondary structure relations between beta-lactamases and penicillin-sensitive D-alanine-carboxypeptidases.
• Limited proteolysis of the penicillin-sensitive D-alanine carboxypeptidase purified from Bacillus subtilis membranes. Active water-soluble fragments generated by cleavage of a COOH-terminal membrane anchor.
• Penicillins and cephalosporins are active site-directed acylating agents: evidence in support of the substrate analogue hypothesis.
• Sequence of active site peptides from the penicillin-sensitive D-alanine carboxypeptidase of Bacillus subtilis. Mechanism of penicillin action and sequence homology to beta-lactamases.
• Amino acid sequence homologies between Escherichia coli penicillin-binding protein 5 and class A beta-lactamases.
• Linear, uncross-linked peptidoglycan secreted by penicillin-treated Bacillus subtilis. Isolation and characterization as a substrate for penicillin-sensitive D-alanine carboxypeptidases.
• Rat hepatic cholesterol 7 alpha-hydroxylase: biochemical properties and comparison to constitutive and xenobiotic-inducible cytochrome P-450 enzymes.
• Isolation and characterization of cDNA clones for cytochromes P-450 immunochemically related to rat hepatic P-450 form PB-1.
• Preparation and characterization of monoclonal antibodies to pregnenolone 16-alpha-carbonitrile inducible rat liver cytochrome P-450.
• 3-(Trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine photolabels a substrate-binding site of rat hepatic cytochrome P-450 form PB-4.
• Hormonal regulation of rat liver microsomal enzymes. Role of gonadal steroids in programming, maintenance, and suppression of delta 4-steroid 5 alpha-reductase, flavin-containing monooxygenase, and sex-specific cytochromes P-450.
• 17 beta-estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement.
• Phenotypic differences in expression of cytochrome P-450g but not its mRNA in outbred male Sprague-Dawley rats.
• Phenobarbital induction of cytochrome P-450 in normal and preneoplastic rat liver: comparison of enzyme and mRNA expression as detected by immunohistochemistry and in situ hybridization.
• Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene.
• Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists.
• Cytochrome P-450 cholesterol 7 alpha-hydroxylase: inhibition of enzyme deactivation by structurally diverse calmodulin antagonists and phosphatase inhibitors.
• Metabolism of methotrexate and gamma-tert-butyl methotrexate by human leukemic cells in culture and by hepatic aldehyde oxidase in vitro.
• Inhibition of human liver folylpolyglutamate synthetase by non-gamma-glutamylatable antifolate analogs.
• Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.
• The structure of phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4. Production and characterization of site-specific antibodies.
• Microheterogeneity of a male-specific rat hepatic cytochrome P-450: existence of three allozymic forms.
• Enzymic and chemical reduction of 2-deaminoactinomycins to free radicals.
• Purification and characterization of the human neutrophil NADH-cytochrome b5 reductase.
• Studies on the chirality of sulfoxidation catalyzed by bacterial flavoenzyme cyclohexanone monooxygenase and hog liver flavin adenine dinucleotide containing monooxygenase.
• Cephalosporin-sensitive penicillin-binding proteins of Staphylococcus aureus and Bacillus subtilis active in the conversion of [14C]penicillin G to [14C]phenylacetylglycine.
• Mechanism of penicillin action: penicillin and substrate bind covalently to the same active site serine in two bacterial D-alanine carboxypeptidases.
• Cleavage of a COOH-terminal hydrophobic region from D-alanine carboxypeptidase, a penicillin-sensitive bacterial membrane enzyme. Characterization of active, water-soluble fragments.
• Constitutively active STAT5b feminizes mouse liver gene expression
• Impact of Neonatal Activation of Nuclear Receptor CAR (Nr1i3) on Cyp2 Gene Expression in Adult Mouse Liver
• Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer
• Long non-coding RNA G23Rik attenuates fasting-induced lipid accumulation in the liver
• Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Constitutively Active STAT5b Feminizes Mouse Liver Gene Expression
• Interplay between GH-regulated, sex-biased liver transcriptome and hepatic zonation revealed by single nucleus RNAseq
• Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing
• Long non-coding RNA G23Rik attenuates fasting-induced lipid accumulation in mouse liver
• Dysregulation of murine long non-coding single cell transcriptome in non-alcoholic steatohepatitis and liver fibrosis
• TCDD dysregulation of lncRNA expression, liver zonation and intercellular communication across the liver lobule
• Data from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Supplementary Figures S1-S9 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Table S1 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Table S4 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Table S5 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Table S2 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Table S3 from Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer
• Dysregulation of murine long noncoding single-cell transcriptome in nonalcoholic steatohepatitis and liver fibrosis
• Plasma Growth Hormone Pulsatility Directly Regulates Male-biased Chromatin Accessibility in Adult Mouse Liver
• Plasma Growth Hormone Pulses Induce Male-biased Pulsatile Chromatin Opening and Epigenetic Regulation in Adult Mouse Liver
• Plasma growth hormone pulses induce male-biased pulsatile chromatin opening and epigenetic regulation in adult mouse liver
• Plasma growth hormone pulses induce male-biased pulsatile chromatin opening and epigenetic regulation in adult mouse liver
• Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
• Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression
• HDI-STARR-seq: Condition-specific enhancer discovery in mouse liver in vivo
• Liver-specific actions of GH and IGF1 that protect against MASLD